Overview

Study to Assess the Safety & Tolerability of a PARP Inhibitor in Combination With Gemcitabine in Pancreatic Cancer

Status:
Completed
Trial end date:
2012-07-01
Target enrollment:
0
Participant gender:
All
Summary
The purpose of this study is to identify a safe and tolerable dose of the drug KU-0059436 that can be given in combination with gemcitabine chemotherapy for the treatment of pancreatic cancer.
Phase:
Phase 1
Accepts Healthy Volunteers?
No
Details
Lead Sponsor:
AstraZeneca
Treatments:
Gemcitabine
Olaparib
Poly(ADP-ribose) Polymerase Inhibitors
Criteria
Inclusion Criteria:

- Histologically or cytologically confirmed adenocarcinoma of pancreas

- Locally advanced or metastatic unresectable disease

Exclusion Criteria:

- No prior anti cancer chemotherapy, radiotherapy (except palliative >4 weeks prior to
entry, endocrine or immunotherapy or use of other investigational agents;